Lenograstim

Lenograstim
Clinical data
Trade names Euprotin, Granocyte, Lenobio, Neutrogin
AHFS/Drugs.com International Drug Names
Identifiers
CAS Number 135968-09-1 N
ATC code L03AA10 (WHO)
ChemSpider none
UNII 6WS4C399GB YesY
 NYesY (what is this?)  (verify)

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator.[1][2] It is developed by Chugai Pharmaceuticals under the brand name Granocyte.

References

  1. ↑ "USAN Council. List No. 340. New names. Lenograstim". Clin. Pharmacol. Ther. 52 (1): 113. July 1992. doi:10.1038/clpt.1992.117. PMID 1284891.
  2. ↑ Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T (July 2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC: 1895135. PMID 15761020.


This article is issued from Wikipedia - version of the Sunday, April 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.